These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 10704627

  • 1. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels.
    Paassilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Bäckström AC, Kesäniemi YA.
    Atherosclerosis; 2000 Mar; 149(1):157-62. PubMed ID: 10704627
    [Abstract] [Full Text] [Related]

  • 2. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.
    Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):727-32. PubMed ID: 9039339
    [Abstract] [Full Text] [Related]

  • 3. [Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate].
    Milewicz T, Krzysiek J, Rogatko I, Sztefko K, Stochmal E, Hubalewska-Dydejczyk A, Jach R, Radowicki S.
    Ginekol Pol; 2011 Mar; 82(3):200-4. PubMed ID: 21735688
    [Abstract] [Full Text] [Related]

  • 4. The insulin-like growth factor-I system and hormone replacement therapy.
    Cardim HJ, Lopes CM, Giannella-Neto D, da Fonseca AM, Pinotti JA.
    Fertil Steril; 2001 Feb; 75(2):282-7. PubMed ID: 11172828
    [Abstract] [Full Text] [Related]

  • 5. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
    Raudaskoski T, Knip M, Laatikainen T.
    Menopause; 1998 Feb; 5(4):217-22. PubMed ID: 9872487
    [Abstract] [Full Text] [Related]

  • 6. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism.
    Karjalainen A, Paassilta M, Heikkinen J, Bäckström AC, Savolainen M, Kesäniemi YA.
    Clin Endocrinol (Oxf); 2001 Feb; 54(2):165-73. PubMed ID: 11207630
    [Abstract] [Full Text] [Related]

  • 7. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [Abstract] [Full Text] [Related]

  • 8. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR, Stuckey BG, Norman RJ, Papalia MA, Drillich A, Bell RJ.
    Menopause; 2008 Jul; 15(6):1065-9. PubMed ID: 18806686
    [Abstract] [Full Text] [Related]

  • 9. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV, Franke HR, Kenemans P.
    Menopause; 2003 Jul; 10(6):550-8. PubMed ID: 14627865
    [Abstract] [Full Text] [Related]

  • 10. Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins.
    Mozzanega B, Babbo GL, Salmaso L, De Toni R, Schiavo A, Mioni R, de Kreutzenberg SV.
    Gynecol Endocrinol; 2007 Jan; 23(1):50-7. PubMed ID: 17484513
    [Abstract] [Full Text] [Related]

  • 11. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [Abstract] [Full Text] [Related]

  • 12. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ.
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [Abstract] [Full Text] [Related]

  • 13. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
    Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E.
    Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
    [Abstract] [Full Text] [Related]

  • 14. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
    Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR.
    Psychoneuroendocrinology; 1999 Aug; 24(6):657-77. PubMed ID: 10399774
    [Abstract] [Full Text] [Related]

  • 15. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex.
    Kam GY, Leung KC, Baxter RC, Ho KK.
    J Clin Endocrinol Metab; 2000 May; 85(5):1918-22. PubMed ID: 10843175
    [Abstract] [Full Text] [Related]

  • 16. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels.
    Cano A, Castelo-Branco C, Tarín JJ.
    Fertil Steril; 1999 Feb; 71(2):261-7. PubMed ID: 9988395
    [Abstract] [Full Text] [Related]

  • 17. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ, Ho KK, Lazarus L.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [Abstract] [Full Text] [Related]

  • 18. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [Abstract] [Full Text] [Related]

  • 19. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ, de Valk-de Roo GW, Gooren LJ, Netelenbos C.
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [Abstract] [Full Text] [Related]

  • 20. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M, Fait T, Kovar J, Poledne R, Ceska R.
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.